NMO
MCID: NRM001
MIFTS: 66

Neuromyelitis Optica (NMO)

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuromyelitis Optica

MalaCards integrated aliases for Neuromyelitis Optica:

Name: Neuromyelitis Optica 38 12 53 25 54 59 37 55 44 15 73
Devic Syndrome 76 53 25
Devic Disease 53 25 59
Devic's Syndrome 12 54
Devic's Disease 12 25
Opticospinal Multiple Sclerosis 73
Devic's Neuromyelitis Optica 53
Devic Neuromyelitis Optica 25
Nmo Spectrum Disorder 53
Optic-Spinal Ms 25
Opticospinal Ms 25
Nmo 53

Characteristics:

Orphanet epidemiological data:

59
neuromyelitis optica
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:8869
ICD10 33 G36.0
ICD9CM 35 341.0
MeSH 44 D009471
NCIt 50 C84934
SNOMED-CT 68 25044007
Orphanet 59 ORPHA71211
MESH via Orphanet 45 D009471
UMLS via Orphanet 74 C0027873
ICD10 via Orphanet 34 G36.0
KEGG 37 H01491

Summaries for Neuromyelitis Optica

NINDS : 54 Neuromyelitis optica (NMO) is an autoimmune disease of the central nervous system (CNS) that predominantly affects the optic nerves and spinal cord. It is sometimes also referred to as NMO spectrum disorder. In NMO, the body's immune system mistakenly attacks healthy cells and proteins in the body, most often those in the spinal cord and eyes. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss. Individuals also develop transverse myelitis, which causes weakness or paralysis of arms and legs,and numbness, along with loss of bladder and bowel control. Magnetic resonance imaging of the spine often shows an abnormality that extends over long segments of the spinal cord. Individuals may also develop episodes of severe nausea and vomiting, with hiccups from involvement of a part of the brain that controls vomiting. The disease is caused by abnormal autoantibodies that bind to a protein called aquaporin-4. Binding of the aquaporin-4 antibody activates other components of the immune system, causing inflammation and damage to these cells. This also results in the brain and spinal cord the loss of myelin, the fatty substance that acts as insulation around nerve fibers and helps nerve signals move from cell to cell.  NMO is different from multiple sclerosis (MS). Attacks are usually more severe in NMO than in MS, and NMO is treated differently than MS. Most individuals with NMO experience clusters of attacks days to months or years apart, followed by partial recovery during periods of remission. Women are more often affected by NMO than men. African Americans are at greater risk of the disease than are Caucasians. The onset of NMO varies from childhood to adulthood, with two peaks, one in childhood and the other in adults in their 40s.

MalaCards based summary : Neuromyelitis Optica, also known as devic syndrome, is related to neuritis and optic neuritis. An important gene associated with Neuromyelitis Optica is AQP4 (Aquaporin 4), and among its related pathways/superpathways are Allograft rejection and Th17 cell differentiation. The drugs Mitoxantrone and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, brain and spinal cord, and related phenotypes are recurrent singultus and visual loss

Disease Ontology : 12 A central nervous system disease characterized by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

Genetics Home Reference : 25 Neuromyelitis optica is an autoimmune disorder that affects the nerves of the eyes and the central nervous system, which includes the brain and spinal cord. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In neuromyelitis optica, the autoimmune attack causes inflammation of the nerves, and the resulting damage leads to the signs and symptoms of the condition.

NIH Rare Diseases : 53 Neuromyelitis optica is an autoimmune disease that affects the spinal cord and optic nerves (nerves that carry visual messages to and from the brain). In neuromyelitis optica, the body's immune system mistakenly attacks healthy cells and a substance called myelin in the spinal cord and eyes. Symptoms may begin in childhood or adulthood. Spinal cord involvement results in transverse myelitis, which may cause pain, paralysis and abnormal sensations in the spine and limbs. Bladder and bowel problems may also develop. Symptoms from optic nerve involvement include eye pain and vision loss from optic neuritis. Other symptoms of neuromyelitis optica may include episodes of nausea, vomiting, and hiccups. Some people have episodes of symptoms months or years apart (the relapsing form), while others have a single episode lasting several months (the monophasic form). In either form, people with neuromyelitis optica often develop permanent muscle weakness and vision loss. The cause of the immune system dysfunction leading to neuromyelitis optica is not known. It usually occurs in only one person in a family. There is no cure, but there are therapies to reduce symptoms during episodes and prevent relapses.

Wikipedia : 76 Neuromyelitis optica (NMO), also known as Devic''s disease or Devic''s syndrome, is a heterogeneous... more...

Related Diseases for Neuromyelitis Optica

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 neuritis 31.5 AQP4 MBP MOG
2 optic neuritis 31.3 AQP4 HLA-DRB1 MBP MOG
3 transverse myelitis 31.0 AQP4 IL17A IL6 MBP
4 encephalitis 30.9 AQP4 GFAP MOG
5 multiple sclerosis 30.9 AQP4 GFAP HLA-DRB1 IL17A IL6 MBP
6 optic nerve disease 30.8 AQP4 MBP MOG
7 myelitis 30.7 AQP4 HLA-DPB1 IL17A IL6 MBP MOG
8 demyelinating disease 30.6 AQP4 IL17A MBP MOG
9 acute transverse myelitis 30.5 AQP4 IL6
10 radiculopathy 30.2 IL17A IL6
11 hypersomnia 30.2 HCRT HLA-DRB1
12 panencephalitis, subacute sclerosing 30.2 MBP MOG
13 allergic encephalomyelitis 30.2 MBP MOG
14 wernicke encephalopathy 30.2 GFAP SLC1A2
15 peripheral nervous system disease 30.2 AQP4 IL6 MBP MOG
16 brain injury 30.1 GFAP IL6 MBP
17 connective tissue disease 30.1 HLA-DPB1 HLA-DRB1 IL6 TNFSF13B
18 acute disseminated encephalomyelitis 30.1 AQP4 HCRT HLA-DRB1 MBP MOG
19 primary progressive multiple sclerosis 30.1 HLA-DRB1 MBP MOG
20 autoimmune disease 30.1 HLA-DRB1 IL17A IL6 MBP MOG TNFSF13B
21 relapsing-remitting multiple sclerosis 30.1 AQP4 IL17A MBP MOG
22 internuclear ophthalmoplegia 30.0 AQP4 HCRT MBP MOG
23 systemic lupus erythematosus 29.9 CD59 HLA-DPB1 HLA-DRB1 IL17A IL6 TNFSF13B
24 takayasu arteritis 29.9 HLA-DPB1 HLA-DRB1 IL6
25 narcolepsy 29.7 AQP4 HCRT HLA-DPB1 HLA-DRB1 MOG
26 neuromyelitis optica spectrum disorder 12.7
27 marburg acute multiple sclerosis 11.4
28 sjogren syndrome 10.5
29 lupus erythematosus 10.5
30 neuropathy 10.5
31 myasthenia gravis 10.4
32 myasthenia gravis congenital 10.4
33 depression 10.4
34 autoimmune disease 1 10.3
35 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
36 hematopoietic stem cell transplantation 10.3
37 hepatitis 10.3
38 adenocarcinoma 10.3
39 encephalopathy 10.3
40 celiac disease 1 10.3
41 dystonia 10.3
42 leber hereditary optic neuropathy 10.3
43 obstructive hydrocephalus 10.2 AQP4 GFAP
44 alexia 10.2 AQP4 MBP
45 chiari malformation 10.2 GFAP MBP
46 anca-associated vasculitis 10.2 HLA-DRB1 IL6
47 scleroderma, familial progressive 10.2
48 biotinidase deficiency 10.2
49 anxiety 10.2
50 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2

Graphical network of the top 20 diseases related to Neuromyelitis Optica:



Diseases related to Neuromyelitis Optica

Symptoms & Phenotypes for Neuromyelitis Optica

Human phenotypes related to Neuromyelitis Optica:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent singultus 59 32 occasional (7.5%) Occasional (29-5%) HP:0100247
2 visual loss 59 32 hallmark (90%) Very frequent (99-80%) HP:0000572
3 respiratory failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0002878
4 peripheral demyelination 59 32 hallmark (90%) Very frequent (99-80%) HP:0011096
5 optic neuritis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100653
6 sensory impairment 59 32 hallmark (90%) Very frequent (99-80%) HP:0003474
7 ocular pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0200026
8 autoimmune antibody positivity 59 32 hallmark (90%) Very frequent (99-80%) HP:0030057
9 neuronal loss in central nervous system 59 32 hallmark (90%) Very frequent (99-80%) HP:0002529
10 nausea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002018
11 abnormality of brain morphology 59 32 frequent (33%) Frequent (79-30%) HP:0012443
12 csf pleocytosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012229
13 paraplegia 59 32 hallmark (90%) Very frequent (99-80%) HP:0010550
14 functional abnormality of the bladder 59 32 hallmark (90%) Very frequent (99-80%) HP:0000009
15 myelitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0012486

MGI Mouse Phenotypes related to Neuromyelitis Optica:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 AQP1 AQP4 GFAP HCRT IL6 MBP
2 growth/size/body region MP:0005378 9.97 AQP1 AQP4 GFAP HCRT IL17A IL6
3 hematopoietic system MP:0005397 9.86 AQP1 AQP4 CD59 IL17A IL6 MBP
4 homeostasis/metabolism MP:0005376 9.81 AQP1 AQP4 CD59 GFAP HCRT IL17A
5 nervous system MP:0003631 9.56 AQP1 AQP4 GFAP HCRT IL6 MBP
6 vision/eye MP:0005391 9.1 AQP1 AQP4 GFAP IL6 MBP MOG

Drugs & Therapeutics for Neuromyelitis Optica

Drugs for Neuromyelitis Optica (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4 Topoisomerase Inhibitors Phase 4
5 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
6 Analgesics Phase 4
7 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
8 Hormones Phase 4,Phase 3,Phase 1,Phase 2
9 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
10 Antibiotics, Antitubercular Phase 4
11 Anti-Bacterial Agents Phase 4
12 Anti-Infective Agents Phase 4
13 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
14 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
15 Antitubercular Agents Phase 4
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
17
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 1,Phase 2 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 3,Phase 1,Phase 2 2921-57-5
21
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
22
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
23
Prednisolone hemisuccinate Experimental Phase 3,Phase 1,Phase 2 2920-86-7
24 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
25 Protective Agents Phase 3,Phase 1,Phase 2
26 Prednisolone acetate Phase 3,Phase 1,Phase 2
27 Gastrointestinal Agents Phase 3,Phase 1,Phase 2
28 Autonomic Agents Phase 3,Phase 1,Phase 2
29 Antiemetics Phase 3,Phase 1,Phase 2
30 Neuroprotective Agents Phase 3,Phase 1,Phase 2
31 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
32 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
35 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
36 Antimetabolites Phase 2, Phase 3,Phase 3
37 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
38 gamma-Globulins Phase 3,Phase 2
39 Immunoglobulins, Intravenous Phase 3,Phase 2
40 Rho(D) Immune Globulin Phase 3,Phase 2
41 Immunoglobulin G Phase 3
42 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
43
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
44
Histamine Approved, Investigational Phase 1, Phase 2 51-45-6, 75614-87-8 774
45
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
46
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
47
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
48
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
49
4-Aminopyridine Approved Phase 2 504-24-5 1727
50
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 6055-19-2, 50-18-0 2907

Interventional clinical trials:

(show all 49)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
2 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Completed NCT01892345 Phase 3 Eculizumab
7 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
8 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
9 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
10 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Active, not recruiting NCT02003144 Phase 3
11 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
12 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
15 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
16 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
17 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
18 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
19 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Completed NCT02249676 Phase 2
20 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
21 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
22 Hematopoietic Stem Cell Transplant in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
23 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
24 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
25 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
26 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
27 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
28 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
29 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
30 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
31 Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Not yet recruiting NCT03605238 Phase 1
32 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
33 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
34 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
35 Pathologic-MRI Findings in Atypical IIDD Completed NCT03121105
36 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
37 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
38 Pediatric NMOSD Observational Study Recruiting NCT03766347
39 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
40 The French Multiple Sclerosis Registry Recruiting NCT02889965
41 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
42 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541 Not Applicable
43 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
44 Scrambler Trial for Pain in NMOSD Active, not recruiting NCT03452176 Not Applicable
45 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
46 Optical Coherence Tomography and Optic Neuritis (OCTON) Active, not recruiting NCT02573792
47 Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China Enrolling by invitation NCT03514030
48 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867 Not Applicable
49 Optic Neuritis Differential Diagnosis Study Not yet recruiting NCT03370965 Not Applicable

Search NIH Clinical Center for Neuromyelitis Optica

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neuromyelitis Optica cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neuromyelitis optica

Genetic Tests for Neuromyelitis Optica

Anatomical Context for Neuromyelitis Optica

MalaCards organs/tissues related to Neuromyelitis Optica:

41
Brain, Spinal Cord, Eye, T Cells, B Cells, Bone, Lung
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Neuromyelitis Optica:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Neuromyelitis Optica

Articles related to Neuromyelitis Optica:

(show top 50) (show all 1603)
# Title Authors Year
1
Association of GTF2IRD1-GTF2I polymorphisms with neuromyelitis optica spectrum disorders in Han Chinese patients. ( 30531019 )
2019
2
A Case of Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder. ( 29780127 )
2018
3
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. ( 29519720 )
2018
4
Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica. ( 29447335 )
2018
5
Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. ( 29249386 )
2018
6
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. ( 29414288 )
2018
7
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis. ( 29794010 )
2018
8
Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders. ( 29789706 )
2018
9
<i>Case Report:</i> Osmotic Demyelination Syndrome in an Adolescent with Neuromyelitis Optica. ( 29896051 )
2018
10
Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy. ( 29676204 )
2018
11
Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. ( 29414283 )
2018
12
Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. ( 29388807 )
2018
13
Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder. ( 29973905 )
2018
14
Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. ( 29913164 )
2018
15
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder. ( 29703264 )
2018
16
B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder. ( 29621743 )
2018
17
Neuromyelitis optica: suicide risk and psychiatric comorbidities. ( 29948241 )
2018
18
Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women. ( 29371414 )
2018
19
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159373 )
2018
20
Mortality in neuromyelitis optica is strongly associated with African ancestry. ( 29892608 )
2018
21
Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. ( 29802557 )
2018
22
Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge. ( 29866760 )
2018
23
Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica. ( 29872456 )
2018
24
The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. ( 29349658 )
2018
25
The evolving mystery of why skeletal muscle is spared in seropositive neuromyelitis optica. ( 29363875 )
2018
26
Corrigendum to &amp;quot;Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder&amp;quot; [Journal of Neuroimmunology 317C (2018) pp. 1-4]. ( 29606296 )
2018
27
Epidemiology of neuromyelitis optica spectrum disorder. ( 29732539 )
2018
28
Cocaine as a potential trigger for Neuromyelitis Optica. ( 29801917 )
2018
29
Persistent microscopic active inflammatory lesions in the central nervous system of a patient with neuromyelitis optica treated with oral prednisolone for more than 40a8^years. ( 29928713 )
2018
30
Teaching NeuroImages: Leber hereditary optic neuropathy masquerading as neuromyelitis optica. ( 29284658 )
2018
31
A Rare Presentation of Neuromyelitis Optica Spectrum Disorders. ( 29434480 )
2018
32
Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. ( 29675599 )
2018
33
Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental inA vitro and rat models of neuromyelitis optica. ( 29428821 )
2018
34
Retinal ganglion cell-inner plexiform and nerve fiber layers in neuromyelitis optica. ( 29375997 )
2018
35
Neuromyelitis Optica: Review and Utility of Testing Aquaporin-4 Antibody in Typical Optic Neuritis. ( 29766684 )
2018
36
Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. ( 29367170 )
2018
37
Mutation of the cellular adhesion molecule NECL2 is associated with neuromyelitis optica spectrum disorder. ( 29627007 )
2018
38
Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. ( 29499441 )
2018
39
Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. ( 29297041 )
2018
40
Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. ( 29695599 )
2018
41
Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? ( 29073350 )
2018
42
Differentiating Neuromyelitis Optica-Related and Multiple Sclerosis-Related Acute Optic Neuritis Using Conventional Magnetic Resonance Imaging Combined With Readout-Segmented Echo-Planar Diffusion-Weighted Imaging. ( 29787495 )
2018
43
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159372 )
2018
44
Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study. ( 29921610 )
2018
45
Neuromyelitis Optica Spectrum Disorder Presenting with Pseudoathetosis. ( 29629549 )
2018
46
Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. ( 29359475 )
2018
47
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )
2018
48
Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. ( 29929977 )
2018
49
Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. ( 29783157 )
2018
50
MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. ( 29449281 )
2018

Variations for Neuromyelitis Optica

Expression for Neuromyelitis Optica

Search GEO for disease gene expression data for Neuromyelitis Optica.

Pathways for Neuromyelitis Optica

GO Terms for Neuromyelitis Optica

Cellular components related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.46 AQP4 HLA-DRB1 IL17A MOG
2 clathrin-coated endocytic vesicle membrane GO:0030669 9.37 HLA-DPB1 HLA-DRB1
3 cell surface GO:0009986 9.35 CD59 HLA-DPB1 HLA-DRB1 MBP SLC1A2
4 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.32 HLA-DPB1 HLA-DRB1
5 MHC class II protein complex GO:0042613 9.26 HLA-DPB1 HLA-DRB1
6 ER to Golgi transport vesicle membrane GO:0012507 8.8 CD59 HLA-DPB1 HLA-DRB1
7 plasma membrane GO:0005886 10.06 AQP1 AQP4 CD59 HLA-DPB1 HLA-DRB1 MBP

Biological processes related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.73 HCRT IL17A IL6 TNFSF13B
2 T cell receptor signaling pathway GO:0050852 9.5 HLA-DPB1 HLA-DRB1 MOG
3 renal water homeostasis GO:0003091 9.48 AQP1 AQP4
4 positive regulation of interleukin-6 secretion GO:2000778 9.46 IL17A MBP
5 water transport GO:0006833 9.4 AQP1 AQP4
6 positive regulation of glial cell proliferation GO:0060252 9.37 GFAP IL6
7 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DPB1 HLA-DRB1
8 multicellular organismal water homeostasis GO:0050891 9.16 AQP1 AQP4
9 positive regulation of T cell proliferation GO:0042102 9.13 HLA-DPB1 IL6 TNFSF13B
10 immune response GO:0006955 9.1 HLA-DPB1 HLA-DRB1 IL17A IL6 MBP TNFSF13B

Molecular functions related to Neuromyelitis Optica according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.5 IL17A IL6 TNFSF13B
2 peptide antigen binding GO:0042605 9.26 HLA-DPB1 HLA-DRB1
3 channel activity GO:0015267 9.16 AQP1 AQP4
4 water channel activity GO:0015250 8.96 AQP1 AQP4
5 water transmembrane transporter activity GO:0005372 8.62 AQP1 AQP4

Sources for Neuromyelitis Optica

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....